Key Information
Chief Investigator: Sejal Saglani
ICTU Collaboration: Operations; Statistics; Database
Email: TREAT_trial@imperial.ac.uk
Website: TREAT trial
Trial registration: ISRCTN 12109108 EudraCT 2019-004085-17
Status: Recruiting
A multi-centre, parallel arm, randomised, open label, controlled, non-inferiority trial of mepolizumab and omalizumab with a run-in to identify Severe Therapy Resistant Asthma (STRA) and Refractory Difficult Asthma.
The trial aims to recruit 500 children with severe asthma aged six to sixteen years into the initial Run-in phase and 150 participants to proceed into the randomised phase which lasts for 52 weeks. Recruited eligible participants will be randomised (1:1) to either omalizumab or mepolizumab
Therapeutic areas contacts
For contact details please visit Therapeutic areas contacts